JP2022551269A5 - - Google Patents
Info
- Publication number
- JP2022551269A5 JP2022551269A5 JP2022520472A JP2022520472A JP2022551269A5 JP 2022551269 A5 JP2022551269 A5 JP 2022551269A5 JP 2022520472 A JP2022520472 A JP 2022520472A JP 2022520472 A JP2022520472 A JP 2022520472A JP 2022551269 A5 JP2022551269 A5 JP 2022551269A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- modified
- positions
- oligonucleotide according
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962909278P | 2019-10-02 | 2019-10-02 | |
| US62/909,278 | 2019-10-02 | ||
| PCT/US2020/053999 WO2021067744A1 (en) | 2019-10-02 | 2020-10-02 | Chemical modifications of small interfering rna with minimal fluorine content |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551269A JP2022551269A (ja) | 2022-12-08 |
| JP2022551269A5 true JP2022551269A5 (https=) | 2023-10-25 |
Family
ID=73038388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520472A Withdrawn JP2022551269A (ja) | 2019-10-02 | 2020-10-02 | 最小フッ素含有量を用いた低分子干渉ｒｎａの化学修飾 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220389430A1 (https=) |
| EP (1) | EP4038191A1 (https=) |
| JP (1) | JP2022551269A (https=) |
| KR (1) | KR20220069103A (https=) |
| CN (1) | CN114761557B (https=) |
| AU (1) | AU2020358016A1 (https=) |
| CA (1) | CA3153026A1 (https=) |
| CL (1) | CL2022000825A1 (https=) |
| IL (1) | IL291841A (https=) |
| MX (1) | MX2022004032A (https=) |
| TW (1) | TW202126809A (https=) |
| WO (1) | WO2021067744A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20250400A1 (es) | 2021-04-12 | 2025-02-11 | Dicerna Pharmaceuticals Inc | Composiciones y metodos para inhibir cetohexoquinasa |
| CA3209418A1 (en) * | 2021-04-14 | 2022-10-20 | Utsav SAXENA | Compositions and methods for modulating pnpla3 expression |
| EP4372085A4 (en) * | 2021-07-16 | 2026-01-21 | Suzhou Ribo Life Science Co Ltd | Nucleic acid, composition and conjugate, container, preparation process and use |
| EP4405368A1 (en) * | 2021-09-22 | 2024-07-31 | Sanegene Bio USA Inc. | 2'-alkyl or 3'- alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides |
| WO2023069495A1 (en) * | 2021-10-19 | 2023-04-27 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides |
| JP2024543195A (ja) | 2021-12-01 | 2024-11-19 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ａｐｏｃ３発現を調節するための組成物及び方法 |
| CN119183476A (zh) * | 2022-04-26 | 2024-12-24 | 上海拓界生物医药科技有限公司 | 氘代化学修饰和包含其的寡核苷酸 |
| TW202526017A (zh) * | 2023-09-14 | 2025-07-01 | 美商Ionis製藥公司 | 用於減少ａｐｏｃｉｉｉ表現的化合物及方法 |
| WO2025191337A2 (en) * | 2024-03-11 | 2025-09-18 | Synerk Biotech Limited | Oligonucleotide terminal phosphate derivatives and method of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| DK2341943T3 (en) | 2008-09-22 | 2019-02-25 | Dicerna Pharmaceuticals Inc | COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS |
| US8691971B2 (en) | 2008-09-23 | 2014-04-08 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| KR101728655B1 (ko) | 2008-12-18 | 2017-04-19 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| CA2950960A1 (en) | 2014-06-06 | 2015-12-10 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
| DK3569711T3 (da) | 2014-12-15 | 2021-02-22 | Dicerna Pharmaceuticals Inc | Ligandmodificerede dobbeltstrengede nukleinsyrer |
| WO2019075419A1 (en) * | 2017-10-13 | 2019-04-18 | Dicerna Pharmaceuticals, Inc. | METHODS AND COMPOSITIONS FOR INHIBITING LDHA EXPRESSION |
| UA128786C2 (uk) * | 2017-10-20 | 2024-10-23 | Дайсерна Фармасьютикалз, Інк | Олігонуклеотид для лікування інфекції гепатиту в |
-
2020
- 2020-10-02 AU AU2020358016A patent/AU2020358016A1/en not_active Abandoned
- 2020-10-02 EP EP20799874.1A patent/EP4038191A1/en not_active Withdrawn
- 2020-10-02 CN CN202080082980.8A patent/CN114761557B/zh active Active
- 2020-10-02 MX MX2022004032A patent/MX2022004032A/es unknown
- 2020-10-02 JP JP2022520472A patent/JP2022551269A/ja not_active Withdrawn
- 2020-10-02 WO PCT/US2020/053999 patent/WO2021067744A1/en not_active Ceased
- 2020-10-02 CA CA3153026A patent/CA3153026A1/en active Pending
- 2020-10-02 US US17/766,153 patent/US20220389430A1/en not_active Abandoned
- 2020-10-02 KR KR1020227014229A patent/KR20220069103A/ko not_active Withdrawn
- 2020-10-02 IL IL291841A patent/IL291841A/en unknown
- 2020-10-05 TW TW109134478A patent/TW202126809A/zh unknown
-
2022
- 2022-04-01 CL CL2022000825A patent/CL2022000825A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022551269A5 (https=) | ||
| TWI823866B (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| CN113164509B (zh) | 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法 | |
| KR102473431B1 (ko) | 안티센스 핵산 | |
| ES2318106T3 (es) | Oligonucleotidos que comprenden segmentos alternos y usos de los mismos. | |
| CN110832077B (zh) | 用于抑制α-ENaC表达的RNAi剂及使用方法 | |
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| JP2022551269A (ja) | 最小フッ素含有量を用いた低分子干渉ｒｎａの化学修飾 | |
| CN115397436A (zh) | 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法 | |
| JP2024505035A (ja) | 中枢神経系における遺伝子発現を阻害するための組成物および方法 | |
| JP2018109015A (ja) | 三環ヌクレオシドおよびこれらから調製したオリゴマー化合物 | |
| TW202334416A (zh) | 用於抑制基質金屬蛋白酶7 (MMP7)之表現的RNAi藥劑、其組成物及使用方法 | |
| JP2025522429A (ja) | 中枢神経系組織への治療薬の送達のための脂質結合体 | |
| CN111212909A (zh) | 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物 | |
| WO2023011360A1 (zh) | 一种增强核酸药物缓释能力的方法 | |
| US20260049309A1 (en) | Regulation of activity of rnai molecules | |
| WO2020181130A2 (en) | Polynucleotide conjugates and uses thereof | |
| JP6826984B2 (ja) | アシル−アミノ−ｌｎａオリゴヌクレオチドおよび／またはヒドロカルビル−アミノ−ｌｎａオリゴヌクレオチド | |
| JP2022520653A5 (https=) | ||
| US20260125682A1 (en) | Chemical modifications of small interfering rna with minimal fluorine content | |
| JP7216381B2 (ja) | Ｒｎａ作用抑制剤及びその利用 | |
| EP4219717A2 (en) | Exon skipping oligomers for muscular dystrophy | |
| WO2024233864A2 (en) | Galnac-conjugated rnai oligonucleotides | |
| TW202430635A (zh) | 用於抑制補體成分C3(C3)表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| HK40084771B (zh) | 用於抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法 |